Biotech · Private company
Arrys Therapeutics
Track this companyFree. Adds Arrys Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- grapiprant and pembrolizumabPhase 2 · Non-small Cell Lung Cancer AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- grapiprantPhase 1 · Microsatellite Stable Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- grapiprant and pembrolizumabPhase 1 · Microsatellite Stable Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC AdenocarcinomaPHASE1_PHASE2 · TERMINATED · started Jan 8, 2019ClinicalTrials.gov NCT03696212 · fetched Nov 12, 2026
- Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal CancerPHASE1 · COMPLETED · started Sep 20, 2018ClinicalTrials.gov NCT03658772 · fetched Nov 12, 2026